Searchable abstracts of presentations at key conferences in endocrinology

ea0005p193 | Reproduction | BES2003

Maternal and neonatal outcomes after conception during cabergoline therapy for hyperprolactinaemia

Booth S , Philip S , Middleton M , Park C , Abraham P , Bevan J

Background: Since receiving its UK licence in 1994, cabergoline [CAB] has become the dopamine agonist of choice for the management of hyperprolactinaemia in most UK endocrine units. Aim: To review the outcomes for the mother and neonate when CAB is taken during conception and into early gestation. Method: Retrospective review of Aberdeen casenotes from all hyperprolactinaemic women of childbearing age on CAB therapy and those of their live born infants. Results: Twenty women w...

ea0003p40 | Clinical Case Reports | BES2002

Differentiated thyroid carcinoma with large bony metastases - what is the best approach?

Watson W , Park C , Abraham P , Bandyopadhyay S , Philip S , Acharya S , Samuel L , Bevan J

The high survival rate for patients with differentiated thyroid carcinoma (DTC) declines markedly in those with bony metastases. We compare the management of two patients with large dominant pelvic metastases.Case 1 63 year old man with R hip pain. Investigation revealed a 10cm lesion in the R hemi pelvis and subsequent imaging and biopsy revealed a 9th rib lesion and metastatic follicular DTC. He underwent 131 I ablation of the normal thyroi...

ea0003p48 | Clinical Case Reports | BES2002

Multidisciplinary management of Cushing's syndrome due to a malignant thymic carcinoid tumour

Park C , Watson W , Abraham P , Acharya S , Bandyopadhyay S , Philip S , Samuel L , Nicolson M , Bevan J

Thymic carcinoma is a rare but aggressive cause of ectopic ACTH secretion, with fewer than 100 reported cases.Hypokalaemic alkalosis was found in a 38 year old woman who presented with a 2-week history of leg swelling, fatigue and dyspnoea. She was not obviously Cushingoid.ACTH-dependent Cushing's Syndrome was confirmed biochemically: urinary free cortisol (UFC) >8500nmol/day and serum cortisol 4060nmol/l, (no suppression on 8...

ea0003p36 | Clinical Case Reports | BES2002

Efficacy and safety of high dose testosterone therapy in partial androgen insensitivity

Bandyopadhyay S , Watson W , Park C , Abraham P , Philip S , Acharya S , Bevan J

Efficacy and Safety of High Dose Testosterone Therapy in Partial Androgen InsensitivityS. Bandyopadhyay, W.A.Watson, C. M.Park, P. Abraham, S. Philip, S. Acharya , J.S. Bevan. Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN.INTRODUCTION: There have been few reports of the efficacy and safety of high dose androgen therapy in men with partial androgen insensitivity (PAI). We report on the responses of a p...

ea0073aep533 | Pituitary and Neuroendocrinology | ECE2021

Improved response to somatostatin analogue (SSA) therapy in acromegaly following treatment pause

Rajan Roby , Bhatt D , Philip S , Graveling AJ , Bashari W , Gurnell M , Abraham P

Background/methodsPatients with uncontrolled acromegaly or receiving high cost medical therapy despite initial treatment, usually transsphenoidal surgery (TSS), were considered for a ¹¹C-methionine PET-CT scan (11C-Met PET-CT). This imaging technique may identify a target for TSS or radiotherapy when MRI appearances are inconclusive1. In preparation, four patients on long-term SSA were taken off treatment 3 months prior to the scan. ...

ea0013p93 | Clinical practice/governance and case reports | SFEBES2007

NICE Guidelines for Adult Growth Hormone replacement: an audit of impact on practice in Scotland

Philip S , Carson M , Howat I , Patterson C , Schofield C , Booth A , Patrick AW , Leese GW , Bevan JS , Connell JMC

Background: National Institute for Clinical Excellence (NICE) guidelines for the use of Growth Hormone (GH) replacement in adults with GH deficiency (GHD) were published in 2003, and subsequently ratified for use in Scotland.Aim: To identify all adults in Scotland currently receiving GH and to assess whether they meet the NICE criteria for starting and continuing GH replacement.Methods: All endocrinologists in Scotland were surveye...

ea0011p910 | Thyroid | ECE2006

Changes in thyroxine requirement in the long-term follow-up of hypothyroid patients

Viswanath AK , Avenell A , Philip S , Acharya S , MacLennan G , Dalziel K , Copland SA , Bevan JS , Abraham P

Background and methodology: There are few data on changes in thyroxine requirement in the long-term follow-up of hypothyroid patients. We carried out a retrospective analysis to evaluate the long-term changes in thyroxine dose and its relationship with age, gender, thyroxine dose at registration and aetiology of hypothyroidism.Results: We identified 5,029 patients from our hospital based thyroid register with a minimum of 4 years follow-up (88% female, 7...

ea0011p913 | Thyroid | ECE2006

What is the most effective screening interval in the long-term follow-up of stable hypothyroid patients on thyroxine?

Viswanath AK , Avenell A , Philip S , Acharya S , MacLennan G , Dalziel K , Pereira O , Copland SA , Bevan JS , Abraham P

Background and methodology: In the long-term surveillance of treated hypothyroid patients, annual surveillance (with thyroid function testing) is widely recommended. This is largely based on consensus, as there is limited evidence to support this practice. Currently around 20,000 patients are registered in our hospital based thyroid register and the majority are on 18 monthly follow-up. We carried out a retrospective analysis to see if there is evidence to support increased fr...

ea0003p148 | Endocrine Tumours and Neoplasia | BES2002

Primary medical management of macroprolactinomas with cabergoline(CAB)

Philip S , Booth A , Abraham P , Kumaravel M , Watson W , Park C , Bandyopadhyay S , Acharya S , Bevan J

Objective: To establish the efficacy of CAB as primary and exclusive therapy in the management of macroprolactinomasMethod: Retrospective case note review of all patients with macroprolactinomas treated with CAB since the drug received a UK licence in 1994. Patients: Sixteen patients (8males, 8 females) with mean age at presentation of 42.3yrs (range 22-72 years) were treated with initial CAB doses ranging from 0.5-1mg/week (median 1mg/week). Results: T...

ea0003p150 | Endocrine Tumours and Neoplasia | BES2002

Patterns and mechanisms of hypercortisolism in association with phaeochromocytoma

Abraham P , Watson W , Park C , Philip S , Bandyopadhyay S , Acharya S , Talbot J , White A , Bevan J

Phaeochromocytoma in association with hypercortisolism is thought to be rare. However we have observed 4 cases in 3 years and question the rarity of this link. In each case there was a dominant adrenal mass (3.6-7.7cm) with contralateral adrenal hyperplasia. Three of the 4 tumours showed increased 123-I-mIBG uptake. Urinary catecholamines ranged from 872-22752nmol/24h (N < 600). Hypercortisolism was present in all 4 patients; sustained in 2 and cyclical in 2. Case 1 (JCEM ...